Hepatitis C Stocks List
Symbol | Grade | Name | % Change |
---|---|---|---|
ENTA | B | Enanta Pharmaceuticals, Inc. | 3.21 |
GNMK | B | GenMark Diagnostics, Inc. | 4.15 |
IONS | F | Ionis Pharmaceuticals, Inc. | 2.95 |
RGLS | D | Regulus Therapeutics Inc. | 13.04 |
UTHR | C | United Therapeutics Corporation | 2.49 |
VRTX | F | Vertex Pharmaceuticals Incorporated | 2.02 |
XTLB | C | XTL Biopharmaceuticals Ltd. | 29.76 |
BMY | F | Bristol-Myers Squibb Company | 1.84 |
INO | F | Inovio Pharmaceuticals, Inc. | 0.44 |
NNVC | C | NanoViricides, Inc. | 13.98 |
SCYX | C | SCYNEXIS, Inc. | -5.24 |
BNTC | F | Benitec Biopharma Limited | 6.18 |
Symbol | Grade | Name | Weight |
---|---|---|---|
FBT | F | First Trust Amex Biotech Index Fund | 9.73 |
PBE | D | PowerShares Dynamic Biotech & Genome | 9.38 |
NVQ | B | QRAFT AI-Enhanced US Next Value ETF | 9.18 |
IEIH | D | iShares Evolved U.S. Innovative Healthcare ETF | 9.15 |
BBP | D | BioShares Biotechnology Products Fund | 8.79 |
View all Hepatitis C related ETFs...
Compare ETFs
Date | Stock | Signal | Type |
---|---|---|---|
2021-03-05 | BMY | Jack-in-the-Box Bearish | Bearish Swing Setup |
2021-03-05 | BNTC | Doji - Bullish? | Reversal |
2021-03-05 | BNTC | New 52 Week Low | Weakness |
2021-03-05 | ENTA | 20 DMA Resistance | Bearish |
2021-03-05 | GNMK | Crossed Above 20 DMA | Bullish |
2021-03-05 | GNMK | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup |
2021-03-05 | INO | Hammer Candlestick | Bullish |
2021-03-05 | INO | Lower Bollinger Band Walk | Weakness |
2021-03-05 | INO | Lizard Bullish | Bullish Day Trade Setup |
2021-03-05 | INO | Doji - Bullish? | Reversal |
2021-03-05 | IONS | Lower Bollinger Band Walk | Weakness |
2021-03-05 | IONS | Stochastic Reached Oversold | Weakness |
2021-03-05 | NNVC | 180 Bullish Setup | Bullish Swing Setup |
2021-03-05 | NNVC | 1,2,3 Pullback Bullish | Bullish Swing Setup |
2021-03-05 | NNVC | Crossed Above 200 DMA | Bullish |
2021-03-05 | NNVC | Crossed Above 20 DMA | Bullish |
2021-03-05 | NNVC | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup |
2021-03-05 | RGLS | Lower Bollinger Band Walk | Weakness |
2021-03-05 | RGLS | Bullish Engulfing | Bullish |
2021-03-05 | SCYX | 50 DMA Support | Bullish |
2021-03-05 | UTHR | 50 DMA Resistance | Bearish |
2021-03-05 | UTHR | Lower Bollinger Band Walk | Weakness |
2021-03-05 | VRTX | Lower Bollinger Band Walk | Weakness |
2021-03-05 | VRTX | Bollinger Band Squeeze | Range Contraction |
2021-03-05 | VRTX | 20 DMA Resistance | Bearish |
2021-03-05 | XTLB | Pocket Pivot | Bullish Swing Setup |
2021-03-05 | XTLB | Slingshot Bearish | Bearish Swing Setup |
2021-03-05 | XTLB | Wide Range Bar | Range Expansion |
2021-03-05 | XTLB | Volume Surge | Other |
2021-03-05 | XTLB | New 52 Week High | Strength |
2021-03-05 | XTLB | Crossed Above 50 DMA | Bullish |
2021-03-05 | XTLB | Crossed Above 20 DMA | Bullish |
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.
Mike's Notes
- TWLO: Here's anoth...
- ABNB: An interesti...
- CGNT: Not a chart ...
- TDOC: One of sever...
- NFLX: I love these...
From the Blog
Popular Now
Featured Articles
- What You Trade Is As Important As How You Trade
- Breakouts, Home Runs & Exponential Returns w/ Kristjan Kullamägi
- Tech Stock Indices: Do Bulls Have A Problem?
- Robinhood Proxies – The Private and Public Markets Can Be Very Connected
- The Rise of Cult Stocks
- Semi-automating Your Trading
- Recommended Stock Trading Books